EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Glutamate Ionotropic Kainate Receptors as Therapeutic Targets in Enzalutamide-Resistant and Neuroendocrine Prostate Cancer

Huan Qu, Pengfei Xu, Joy C Yang, Fan Wei, Junwei Zhao iD, Leyi Wang iD, Eva Corey iD, Nicholas Mitsiades, Kit Lam, Kenneth A Iczkowski, Yuanpei Li, Allen C Gao und 2 weitere

International Journal of Molecular Sciences · 02.07.2026 · 27 (13) · 5945

DOI: 10.3390/ijms27135945 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 02.07.2026. Verfasst von Huan Qu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urologic Surgery, School of Medicine, University of California, Davis, CA 95817, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Drug Resistance, Neoplasm, Kainic Acid Receptors, Phenylthiohydantoin. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, United States Department of Defense, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment-induced neuroendocrine prostate cancer (t-NEPC) is the major form of resistance to androgen receptor signaling inhibitors (ARSI) in advanced prostate cancer, characterized by pronounced invasiveness and lineage plasticity. Through in-depth analysis of prostate cancer cohorts, we found that glutamate ionotropic receptor kainate (GRIK) family members, specifically GRIK2 and GRIK5, are highly expressed in neural lineage plastic prostate cancer cells, NEPC patient-derived xenografts (PDX), and NEPC patient samples. Their expression positively correlates with neuroendocrine markers and inversely correlates with androgen receptor (AR) activity. Additionally, functional analyses indicated that AR has a direct transcriptional inhibitory effect on GRIK2 and GRIK5, and the absence of AR signaling leads to the upregulation of GRIK2 and GRIK5. Further RNA sequencing analysis revealed that GRIK5 silencing reprograms the cellular transcriptome, resulting in significant downregulation of AR signaling and fatty acid metabolism, while simultaneously activating immune and inflammatory responses in enzalutamide-resistant prostate cancer cells. In both cell line and NEPC PDX organoid models, loss of GRIK5 impaired proliferation and clonogenic growth. Notably, GRIK5 also contributes to enzalutamide resistance. Pharmacological evaluation revealed that Pan-GRIK antagonists exhibit anti-tumor activity, although the required relatively high concentrations suggest that more potent therapeutic strategies should be developed. Collectively, this study establishes that GRIK family members play critical roles in enzalutamide resistance and NEPC progression, highlighting GRIK signaling as a potential therapeutic target for overcoming lineage plasticity in prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsDrug Resistance, NeoplasmKainic Acid ReceptorsPhenylthiohydantoinNeuroendocrine TumorsCarcinoma, NeuroendocrineMaleHumansBenzamidesNitrilesAnimalsCell Line, TumorReceptors, AndrogenMiceGene Expression Regulation, NeoplasticAmidesSignal TransductionXenograft Model Antitumor AssaysGluK2 Kainate Receptor

Stichwörter der Autor:innen

NEPCandrogen receptorenzalutamide resistanceglutamate ionotropic kainate receptorsneural lineage plasticityprostate cancer

Substanzen

BenzamidesNitrilesenzalutamideKainic Acid ReceptorsPhenylthiohydantoinReceptors, AndrogenAmidesGluK2 Kainate Receptor

Autor:innen und Institutionen

  • Department of Urologic Surgery, School of Medicine, University of California, Davis, CA 95817, USA.
  • Department of Biochemistry and Molecular Medicine, School of Medicine, University of California, Davis, CA 95817, USA.
  • Graduate Group in Integrative Pathobiology, University of California, Davis, CA 95817, USA.
  • Department of Urology, University of Washington, Seattle, WA 98195, USA.
  • Davis Comprehensive Cancer Center, University of California, 4645 2nd Ave, Research III Bldg, Suite 2300C, Sacramento, CA 95817, USA.
  • Department of Internal Medicine, School of Medicine, University of California, Davis, CA 95817, USA.

ORCID-Profile: Junwei Zhao, Leyi Wang, Eva Corey, Chengfei Liu

Förderung

  • NCI NIH HHS
  • United States Department of Defense
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Qu, H., Xu, P., Yang, J. C., Wei, F., Zhao, J., Wang, L., Corey, E., Mitsiades, N., Lam, K., Iczkowski, K. A., Li, Y., Gao, A. C., Dall'Era, M., & Liu, C. (2026). Glutamate Ionotropic Kainate Receptors as Therapeutic Targets in Enzalutamide-Resistant and Neuroendocrine Prostate Cancer. International Journal of Molecular Sciences, 27(13), 5945. https://doi.org/10.3390/ijms27135945

Vancouver

Qu H, Xu P, Yang JC, Wei F, Zhao J, Wang L, et al. Glutamate Ionotropic Kainate Receptors as Therapeutic Targets in Enzalutamide-Resistant and Neuroendocrine Prostate Cancer. International Journal of Molecular Sciences. 2026;27(13):5945. doi:10.3390/ijms27135945

BibTeX
@article{Qu2026,
  author = {Qu, Huan and Xu, Pengfei and Yang, Joy C and Wei, Fan and Zhao, Junwei and Wang, Leyi and Corey, Eva and Mitsiades, Nicholas and Lam, Kit and Iczkowski, Kenneth A and Li, Yuanpei and Gao, Allen C and Dall'Era, Marc and Liu, Chengfei},
  title = {Glutamate Ionotropic Kainate Receptors as Therapeutic Targets in Enzalutamide-Resistant and Neuroendocrine Prostate Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {13},
  pages = {5945},
  doi = {10.3390/ijms27135945}
}
Kostenlos starten →